Immunic Inc President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a third-quarter update.
Dr Vitt starts by describing the quarter as a “very eventful and positive quarter for us, dominated by a key message” – positive interim data from its Phase 2 CALLIPER trial of vidofludimus calcium in Progressive Multiple Sclerosis.
The financial aspect was also discussed, with the company claiming a cash reserve of $60 million as of the last quarter.
The interview highlights the company’s efforts to bolster its intellectual property portfolio, citing a notice of allowance from the US Patent Office for the vidofludimous calcium dose strength patent.
Dr Vitt discusses the company’s focus on business development during the current quarter, expressing confidence in the data and molecules its bringing to discussions with potential partners. He says that “the focus for the company is clearly on the business development side… we [also] continue execution of the vidofludimous MS programs and also prepare a potential phase 2 clinical study for IMU-856.”
Proactive United States